NCM
CBAY

Nantahala Capital Management’s Cymabay Therapeutics CBAY Stock Holding History

Nantahala Capital Management’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-553,307
Closed -$6.06M – 154
2023
Q2 		$6.06M Sell
553,307
-1,236,796
-69% -$11.5M 0.74% 45
2023
Q1 		$15.6M Sell
1,790,103
-460,456
-20% -$3.69M 1.5% 22
2022
Q4 		$14.1M Sell
2,250,559
-224,100
-9% -$852K 1.27% 28
2022
Q3 		$8.66M Sell
2,474,659
-169,647
-6% -$609K 0.85% 45
2022
Q2 		$7.8M Buy
2,644,306
+750,309
+40% +$1.79M 0.68% 50
2022
Q1 		$5.89M Sell
1,893,997
-106,145
-5% -$334K 0.41% 62
2021
Q4 		$6.76M Buy
+2,000,142
New +$7.59M 0.42% 70

Other funds holding CBAY

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PA
Perceptive Advisors New York $5.06B AUM 314.02% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.98B AUM 737.95% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return